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Abstract
Objectives. To estimate the cost-effectiveness of etanercept (ETN) plus usual care (including NSAIDs)
compared with usual care alone (including NSAIDs) in patients with severe AS in Germany.
Methods. A mathematical model previously applied to the UK was adapted using resource use and cost
data (for 2007) from the national database of the German Collaborative Arthritis Centres. Social health
insurance (SHI) and societal perspectives were analysed. Assumptions on initial response and changes
in health-related quality of life were based on Phase III randomized controlled trials. Initial treatment
response according to British Society for Rheumatology guidelines were assumed as a conservative
estimate in the German context. Long-term disease progression was based on the available literature.
Incremental cost–effectiveness ratios (ICERs) were expressed as euros/quality-adjusted life year (QALY),
for a cohort of 1000 patients over 25 years. Sensitivity analyses explored uncertainty in results.
Results. In the base case, ETN plus usual care (including NSAIDs) yielded 1475 more QALYs at an
additional cost of E80 827 668 (SHI) or E32 657 590 (societal) leading to an ICER of E54 815/QALY and
E22 147/QALY, respectively. Over a shorter time horizon of 10 years, the ICERs were E59 006 and
E29 815 for SHI and societal viewpoints, respectively. Assumptions having the largest impact on results
included withdrawal rates from ETN, quality of life, disease costs and initial response.
Conclusions. Cost-effectiveness for ETN in patients with severe AS in Germany differs according to the
cost perspective. Study estimates were higher than in the UK but comparable with reported cost-
effectiveness of anti-TNF treatments in patients with RA in Germany.
Key words: Tumour necrosis factor, Quality of life, Cost-effectiveness, Cost–utility, Economic evaluation,
Ankylosing spondylitis.
Introduction
For patients with AS failing drug treatment with NSAIDs,
TNF-a inhibitors are currently the most promising treat-
ment option and the only alternative for patients with
active progressive disease. Recommendations on the
use of anti-TNF treatment in patients with AS proposed
by the international assessment in AS in 2005 [1] define
patients eligible for treatment with active disease
for 54 weeks in terms of BASDAI54 (a scale of 0–10,
where 10 = worst). In the UK, a further criterion for eligibil-
ity to be met is a spinal visual analogue scale (VAS)54 U
[2]. Response to treatment is defined as a 50% relative
change in BASDAI or absolute change of 20 mm (on a
scale between 0 and 100) and expert opinion in favour
of continuation. In the UK additionally, a reduction of the
spinal VAS52 U is applied.
The use of biologic agents in the treatment of AS has
emphasized the need for information about the current
burden of disease to estimate and answer more fully the
questions on the cost-effectiveness of these drugs [1, 3].
Furthermore, to support rational decision making on the
financing of TNF-a inhibitors in patients with severe AS,
economic model-based evaluations are a useful tool that
extrapolates what is relatively short-term data to
long-term outcomes [4]. Studies conducted for several
countries have reported on the cost-effectiveness of eta-
nercept (ETN): UK [5], The Netherlands [6]; of adalimumab:
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UK [7]; and of infliximab: UK [8, 9], The Netherlands [6],
Spain [10] and Canada [11]. However, transferability from
one country to another is usually restricted [12, 13]. Thus,
country-specific evaluations are required that take into
account country-specific features such as treatment poli-
cies, epidemiology of AS, service patterns and unit costs.
The aim of the present study was to adapt an existing
economic model, previously applied to the UK setting [5],
to the German health care system and to treatment
patterns typical of rheumatological care in Germany. The
adapted model was used to estimate the cost-
effectiveness of ETN treatment in combination with
usual care (including NSAIDs) for patients with severe
AS in Germany over the long term, with both international
and German-specific treatment regimens in comparison
with usual care (including NSAIDs) alone. Analyses from
both the German social health insurance (SHI) and
societal perspectives were performed.
Methods
Overview
As in the earlier UK analysis [5], the model uses both the
BASDAI and the BASFI to represent response and effi-
cacy of treatment [14, 15]. These measurements are vali-
dated and established measurements in AS and have
been shown to have strong associations with both dis-
ease costs and utilities [9, 11]. The current study has
been constructed around these relationships and utilizes
changes in BASDAI and BASFI measurements to predict
changes in health-related quality of life (HRQoL) and
German-specific disease costs.
The model was developed in Microsoft Excel and was
used in the current study to compare ETN plus usual care
(including NSAIDs) with usual care (including NSAIDs)
alone. British Society for Rheumatology (BSR) guidelines
for ETN [2] for defining treatment response were applied
[16]. The cost perspective in the UK study involved direct
health care costs only according to the National Institute for
Health and Clinical Excellence (NICE) reference case for
conducting economic evaluations. The current study for
Germany included assessments of both direct costs only
(SHI perspective) and direct and indirect costs (societal
perspective). Patient-level data from Phase III randomized
controlled trials (RCTs) informed clinical effectiveness and
changes in HRQoL [16–19]. Long-term disease progres-
sion is based on published evidence, and the costs and
benefits extrapolated for a time horizon of 25 years.
Cost-effectiveness estimates defined as the incremental
costs per quality-adjusted life years (QALYs) are calculated
for both shorter and long-term time horizons. Future costs
and benefits are discounted at 5% in accordance with cur-
rent German recommendations [20, 21].
Data
The pivotal evidence used in the model is derived
from a European multicentre, randomized, double-blind,
placebo-controlled trial evaluating the safety and efficacy
of ETN 50 mg once weekly compared with 25 mg twice
weekly in subjects with AS or placebo for 12 weeks [16].
As there was no significant difference in outcomes, data
from the two ETN arms were pooled. This outcomes evi-
dence is supported by data from a predominantly
US-based RCT, where patients were randomized to re-
ceive ETN 25 mg twice weekly or placebo for 24 weeks
supplemented by 4-year evidence from an open-label ex-
tension [18, 22].
HRQoL data collected during the European study are
used to model changes in utilities. As >88% of patients in
the placebo arm of the RCTs received NSAIDs, these data
were used to inform the comparator arm. Table 1 shows
the patient demographics from the clinical studies.
German-specific AS disease costs are derived from a
retrospective (12-month) analysis examining the direct
and indirect costs of AS patients (n= 433 with BASDAI
scores and n= 220 with BASFI scores) attending
24 rheumatology outpatient centres in Germany [23, 24].
Comparison of the German data set used to estimate dis-
ease costs with the data set used in the UK economic
evaluation is presented in Table 1.
Clinical pathway
The current model follows the BSR guidelines as they offer
explicit criteria for a treatment algorithm, as is needed for
health economic modelling. Therefore, the model as-
sumes that all patients have tried and failed to respond
to at least two consecutive NSAIDs and have a BASDAI
measurement 540 before entering the model. To con-
tinue on treatment with ETN, patients must respond to
treatment where response is defined as: reduction of
BASDAI to 50% of the pre-treatment value or a fall of
52 U (scale 0–10) and a reduction in the spinal pain
VAS of 52 U. Based on RCT evidence [16, 17], and
using a similar approach to that reported in Ara et al. [5],
67% respond to ETN at Week 12 [16] and 55% continue
to respond to ETN at Week 24 [16, 17]. In the comparator
arm, the corresponding response rates are 24 and 16%
[16] at Weeks 12 and 24 [16, 17], respectively. It is
assumed that 10% withdraw from ETN each year
[25, 26]. On withdrawal of treatment it is assumed that
patients continue to receive NSAIDs.
Estimating benefit
The magnitudes of initial efficacy were derived from
patient-level data using patients with a baseline BASDAI
of 540 [16, 17]. The mean BASDAI and BASFI meas-
urements at Weeks 12 and 24 for responders and
non-responders to treatment (as defined by the BSR
criteria) and reported in the UK cost-utility analysis [5]
were used as a conservative approach to reflect the
German setting.
For responders to treatment, open-label data suggest
that initial response to ETN is sustained over a further
4 years [19]. We therefore assumed in the model that re-
sponse at Week 24 would be maintained up to 4 years.
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Beyond this point, patients are subject to possible
long-term treatment withdrawal and to changes in BASFI
measurements. For patients who continue responding to
treatment, it is assumed that their BASDAI and BASFI
measurements remain constant at the levels observed at
Week 24 in the RCTs. For patients who withdraw from
treatment, it is conservatively assumed that BASDAI and
BASFI measurements revert back to baseline values
immediately on withdrawal. Alternative assumptions are
considered in sensitivity analyses.
While patients with AS will suffer from a natural progres-
sion of disability, there is a lack of evidence on possible
changes in BASDAI and BASFI measurements in
Germany. Ara et al. [5] used evidence for natural progres-
sion of the disease derived from a cross-sectional survey
of >100 UK AS patients, which reported a mean absolute
change in BASFI of 0.7 (scale 0–100) per annum [9].
Similar rates have been reported from a 5-year longitudin-
al study in 74 UK patients in which BASFI increased
1.26 (95% CI 0.13, 2.29) U per annum [27]. With mortality
risk equal in both arms, German age- and sex-specific
life tables were adjusted using a standardized mortality
ratio of 1.5 [28, 29].
Quality of life
The current model has been developed based on project-
ing patients’ long-term movements in BASDAI and BASFI
measurements. These clinical outcomes have been
mapped onto a generic indirect utility instrument, the
EuroQol (EQ)-5D. Choosing not to adjust for BASDAI/
BASFI may not be discriminative or responsive in differ-
ences between different levels of disease severity and
preference-based assessments for these health states.
As in the UK analysis [4], life years were transformed
into QALYs using a relationship derived from the
BASDAI, BASFI and EQ-5D data collected during
the European RCT [utility = 0.923 (0.004BASFI)
(0.004BASDAI); R2 = 0.52].
Estimating resource use
Drug and monitoring costs
The sick fund cost per 50 mg vial of ETN in Germany is
E418.20 (2007 values) and the dose is 50 mg once weekly
[30]. In the UK, analysis used a price of £89.38 per 25 mg
vial given twice weekly (i.e. £178.76 for 50 mg). The price
differences for ETN can partly be explained by currency
exchange rates. In the UK study [5], the price year is not
explicitly stated but resource use from December 2003 to
June 2004 is described, and the article refers to ‘Annual
disease costs (2006)’. Assuming a price year for the UK
cost calculations of 2006, the German price of ETN for the
same year is E286.19 (2006 year average exchange
rate of E1 = GBP 0.68434 [31]), or looked at another way
the UK price of £178.76 is approximately equivalent to
E261.22. Further, it needs to be considered that in
Germany value-added tax (VAT) of 19% is fully appliedT
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to drugs that are being distributed by pharmacists, where-
as VAT in the UK is 0%. Costs of ETN are larger in the first
3 months due to the additional set-up and monitoring
costs (Table 2). The monitoring and administration
assumptions (quantities) come from BSR guidelines [2]
and are valued using German prices [32].
Disease costs
We used data from the national database of the German
Collaborative Arthritis Centres previously described in
detail [23], provided to us by the German Rheumatism
Research Centre as an update of 2007. In brief, rheuma-
tologists in 24 arthritis centres have recorded the clinical
data of all outpatients with inflammatory rheumatic dis-
eases once a year since 1993 and patients have answered
a comprehensive questionnaire. The rheumatologists are
supposed to register each outpatient with an inflammatory
disease, except those who refuse to participate. The data-
base comprises newly referred and prevalent cases.
Patients seen on a regular basis are registered once a
year. Thereby data on resource utilization have also
been routinely collected [33].
Assessment of annual resource use was based on
these data for 2007 [24]. Data of adult outpatients with
AS, who were enrolled in the national database of the
German Collaborative Arthritis Centres in 2007, were ana-
lysed. The total numbers of patients for the analyses with
BASDAI/BASFI measurements available and who had not
received treatment with biologics were: n= 433 (BASDAI)
and n= 220 (BASFI). Data on health care consumption,
out-of-pocket expenses (including transportation costs)
and productivity losses were derived from doctors
and patients. For example, of the 433 BASDAI-grouped
AS patients, 392 (90.5%) answered the annual patient
TABLE 2 Summary of key model parameter assumptions and the values used
Model parameter Value Parameter 1 Parameter 2 Distribution Source
ETN responders
At Week 12 0.666 203 305  Van der Heijde et al. [16]
At Week 24 0.554 169 305  Van der Heijde et al. [16],
Davis et al. [17]
Annual withdrawal rate from ETN 0.10 13.2 132  Tahir et al. [25],
Kristensen et al. [26]
Sustained response period with ETN 4 years Davis et al. [19]
Quality-of-life: utility (EQ-5D) Multivariate
normal
Van der Heijde et al. [16],
Ara et al. [5]
BASFI 0.0043 0.0007
BASDAI 0.0040 0.0008
Constant 0.9235 0.0170
Standardized mortality rates
(assumed equal in both arms)
1.50 17 26.08  Lehtinen [28]
Total treatment costsa E5466 Fixed Rote Liste Service
GmbH [30], KBV: EBM;
V.7.0; www.kbv.de [32]
First 3 months
Subsequent 3 months E5444 Fixed
Annual AS disease costs: direct
(log transformed)
Univariate
normal
The national database
of the German
Collaborative Arthritis
Centres [23, 24]
Direct costs only (SHI perspective)
BASFI 0.0052
(95% CI 0.0004,
0.0109)
Constant 8.1508
(95% CI 7.8590,
8.4426)
Direct and indirect costs (societal perspective)
BASFI 0.022
Constant 8.1524
(95% CI 7.4564,
8.8483)
Discount rate per annum
Costs, % 5 IQWIG [20], Hannover
Consensus [21]Benefits, % 5
Long-term disease progression measured using annual changes in BASFI (scale 0–100), per annum
Usual care 0.7 Ara et al. [5],
Kobelt et al. [9]
ETN non-responders 0.7
ETN responders 0.7 Ara et al. [5],
Van der Heijde et al. [16],
Davis et al. [17]
aAdministration and monitoring resource use with ETN assumed to include radiology (chest X-ray), full blood count, ESR and
biochemical profile. Resource use valuation in the first 3 months assumes: 1/4/4/1 U. Resource use valuation in subsequent
3 months assumes: 0/1/1/1 U.
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questionnaire about general health- and disease-related
questions and resource utilization, so that questions con-
cerned the cost calculations. In the remainder of patients
[41 (9.5%)], calculations were based on physician docu-
mentation only. Productivity losses were assessed by
both the human capital approach (HCA) and the friction
cost approach [23]. The friction period was applied only to
patients on permanent retirement for health reasons and
not to those on sick leave. The sick leave days are the
cumulated numbers of absence days due to the respect-
ive disease. Productivity losses were then appraised by
assuming that a day of lost productivity costs society as
much as the average daily German wage estimated by
population data.
We based disease costs on the resource utilization from
a German AS patient sample to establish the total annual
direct and indirect costs attributable to AS patients in
Germany. Resource consumption quantities over 1 year
were initially valued using prices for the year 2002 and
then inflated to their 2007 values according to the
German health care-specific price inflation index [34].
Direct costs included physician visits, drugs (e.g.
DMARDs, NSAIDs and Coxibs), non-drug treatments
(e.g. physical therapy, endoprosthetic surgery), diagnostic
and monitoring procedures (e.g. imaging), but excluding
laboratory tests, inpatient treatment (in acute hospitals
and in rehabilitation clinics) and out-of-pocket expenses.
Drug and hospital costs were taken from various sources
[23]. Indirect costs (productivity losses) included sick
leave and permanent work disability and were calculated
using the HCA.
The current analysis is based on data for 2007 of all
outpatients with confirmed diagnoses of AS, and had
been in rheumatological care for at least 1 month and
had not received biologic treatment. Costs were calcu-
lated for each patient for the 12 months preceding the
day of documentation. Huscher et al. [23] collected
BASDAI and BASFI since 2005. Patients were grouped
according to BASDAI/BASFI in steps of 10 score units.
A unique relationship between BASDAI and BASFI
measurements and German annual costs was established
and used to estimate the costs offset by improvements in
disability (Table 2). Costs associated with NSAIDs were
assumed to be included in the annual disease costs as
61% of patients in the National database of the
Collaborative Centres for Rheumatic Diseases (NCCRD)
cohort (with BASDAI scores and 51% with BASFI scores)
received NSAIDs. Annual disease costs also included
other drugs such as DMARDs. We used a German sick
fund price of E418.20 per 50 mg ETN injection in the
base case analysis. The assumed annual cost of ETN ad-
ministration and monitoring wasE21 777, with an addition-
al intensive monitoring cost of E22 in the first 3 months.
Analysis and model development
A similar methodology to that employed in the UK eco-
nomic model of ETN in severe AS [5] was used to simulate
the health care costs and benefits of 1000 hypothetical
patients (each treated with ETN plus usual care or usual
care alone), over a 25-year time horizon for the German
health care setting. A further adaptation of the model to
Germany was the evaluation of both direct health care
costs and indirect costs.
The baseline patient characteristics were sampled from
the demographics of the European study RCT, ankylosing
spondylitis etanercept study 314 (AS314) (Table 1). The
general structure of the model involves an individual sam-
pling procedure to attribute a response in terms of BASFI
and BASDAI to a proportion of patients on treatment.
Model parameters, base case values and probability
distributions used to generate each simulation for the
German setting are presented in Table 2. Health effects
and costs were estimated using the resource use and
cost data from the national database of the German
Collaborative Arthritis Centres described above for the
year 2007 (based on total sample, n= 433 cases). A SHI
perspective (direct costs only) and a societal perspective
(direct and indirect costs) were analysed. Clinical assump-
tions used in the original model were based on individual
patient data from Phase III RCTs to inform the proportion
and magnitude of initial response and changes in HRQoL.
Definition of initial treatment response according to BSR
guidelines were assumed to be a conservative estimate
of initial response in the German context because of the
inclusion of the spinal VAS criterion, which is generally
not used in Germany. Assumptions on long-term disease
progression were derived from published literature.
Incremental cost–effectiveness ratios (ICERs) are calcu-
lated in euros/QALY gained for an extrapolated 25-year
time horizon. To test for uncertainty in the model results,
all key assumptions used in the base case were varied in
one-way sensitivity analyses.
Results of the AS costing evaluation
The mean annual total costs per patient estimated using
BASDAI groups was E8401 comprising direct costs of
E3679 (44%) and indirect costs of E4721 (56%). Using
BASFI groups resulted in a total cost per patient of
E8457 with E3403 (40%) direct and E5054 (60%) indirect
costs, respectively. Proportionally speaking, costs relating
to treatment with DMARDs represented 5.4% (BASDAI
data) to 4.5% (BASFI data) of total costs. Costs relating
to treatment with NSAIDs as part of Other Drugs e.g.
including Coxibs, represented 8.0% (BASDAI data) to
12.4% (BASFI) of total mean costs. The numbers and per-
centages of patients in each of these bands together with
mean annual costs are shown in Fig. 1. Both types of cost
accelerate steeply with worsening disease. Figure 1a and b
suggest that annual mean direct costs do not vary mark-
edly across the lower level BASDAI/BASFI bands.
However, for patients with BASDAI/BASFI measurements
>50, indirect costs have a much greater impact and are
substantially higher than for those with BASDAI/BASFI
measurements <50. Consequently, total annual costs in-
crease sharply for patients with BASDAI/BASFI measure-
ments of 550 as shown in Fig. 1c and d. On average,
indirect costs represent 76% of total annual costs in
2126 www.rheumatology.oxfordjournals.org
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patients with BASFI measurement >50 compared with
27% on average for those with measurements 450.
Corresponding values for BASDAI are 71 and 34%,
respectively.
Individual patient-level data were not available for
Germany, but as in the original UK analysis it was assumed
that the data on costs were skewed [35]. Linear regres-
sions on the log-transformed costs were performed. A re-
lationship was established between BASDAI/BASFI
measurements and mean overall annual costs: (BASDAI
R2= 0.951; BASFI R2= 0.822) and both were significant
predictors (P< 0.000) of the log-transformed costs. We
chose to use the BASFI regression model to predict
annual AS disease costs (Table 2) in the base case as
we wanted to explore later, alternative assumptions con-
cerning (BASFI) disease progression. However, we also
conducted a scenario replacing the BASFI regression
with the BASDAI regression to explore the impact on
costs and effectiveness. We also conducted two further
scenarios analysing the impact of delaying BASFI progres-
sion by a period of some months and a final scenario using
alternative assumptions on initial response to treatment.
Several studies have reported on the time to relapse
after discontinuation. Brandt et al. [36] reported on the cu-
mulative prevalence of relapse after discontinuation of
ETN as part of a 54-week open observational study. In
the study, 26 AS patients received 25 mg s.c. ETN twice
weekly after several months of discontinuation following a
6-month RCT with the same agent. The authors reported
that the data indicated that more than two-thirds of the
patients already had a relapse after 12 weeks and almost
all patients had a relapse after 24 weeks. In a previous
study the same authors reported that, after discontinuation
of ETN, 75% of patients showed a relapse after a mean of
6 weeks within a follow-up period of 3 months [37].
Results
Cost-effectiveness
Table 3 shows the resulting changes in total mean dir-
ect and indirect costs, and the total QALYs gained by
a cohort of 1000 patients in the ETN and comparator
arms over the 25-year period. Over the long term, the
total incremental discounted QALYs gained by a cohort
of 1000 patients was 1475 (UK 1585) at an additional cost
of E80 828K (SHI) or E32 658K (societal) giving an in-
cremental cost per QALY of E54 815 (SHI) or
E22 147(societal).
Sensitivity analysis
As has been described earlier, a number of one-way sen-
sitivity analyses were performed to test for uncertainty.
The results are presented in Table 4 and illustrated as
tornado diagrams (Fig. 2). Three variables appear to
FIG. 1 Mean annual costs with (a) BASFI (n= 220) and (b) BASDAI group (n= 433) and percentage of indirect cost with
(c) BASFI (n= 220) and (d) BASDAI (n= 433).
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have a large impact on the 25-year results from both cost
perspectives. First, lowering the annual withdrawal rate
from ETN treatment from 10 to 5% resulted in ICERs ran-
ging from E6.7K (societal) to E36.6K (SHI) per QALY. On
the other hand, increasing the rate of withdrawal to 20%
resulted in ICERs ranging from E55.7K (societal) to
E81.4K (SHI). Secondly, when using the 95% CIs for dis-
ease costs, ICERs range from E47.2K to E57.9K per
QALY (SHI) and from cost saving to E53.4K per QALY
(societal). Thirdly, when using the 95% CIs to represent
benefits associated with HRQoL, the ICERs range from
E40.7K to E83.9K (SHI) and from E16.2K to E33.9K (so-
cietal) per QALY. The discount rate and BASFI progres-
sion rate had less influence on direct costs, but
comparatively somewhat greater importance for indirect
costs.
Using alternative assumptions regarding initial response
by using the upper CI from the AS314 and Davis trials
essentially includes values closer to a situation where ini-
tial response was defined without the spinal VAS (Table 4).
The ICERs decrease to E38.0K (SHI) and E4.9K (societal).
In a second scenario, we replaced the BASFI regression
to predict annual disease costs with the BASDAI regres-
sion. The ICERs increased only by 1.5% for the SHI per-
spective but increased by 57.6% for the societal
perspective (Table 4). As mentioned earlier, patients in
the ETN arm comprise a proportion of patients who con-
tinue responding to treatment and a proportion who with-
draw. The former incur high treatment costs but
comparatively low disease costs, while the latter incur
low treatment costs but the costs associated with
increased disease severity. The average costs are an ag-
gregate of all the patients in the ETN treatment arm.
Likewise, patients in the comparator arm incur higher dis-
ease costs relative to the ETN treatment arm. In a final
scenario, the results were robust to delaying BASFI pro-
gression by 3 months after withdrawal of ETN treatment.
Discussion
When calculated from a societal perspective the results
of this study demonstrated that ETN treatment in AS
patients is comparable to reported estimates using
anti-TNF agents in patients with other active rheumatic
diseases in Germany such as RA. In a recent study,
Schulze-Koops et al. [38, 39] estimated the cost-
effectiveness of ETN in combination with MTX compared
with MTX monotherapy in patients with RA in Germany
from the societal perspective. For a time horizon of
10 years, ETN in combination with MTX resulted in an
additional 1.09 QALYs at an additional E42 662 per pa-
tient giving an ICER of E38 682 per QALY. In our study,
ETN in combination with usual care (including NSAIDs)
generated comparable QALYs of 1.12 (per patient) by
10 years, at an increased additional cost of E33 376 yield-
ing an ICER of E29 815 per QALY. In a second study,
Rubbert et al. [40] reported on the cost-effectiveness of
using rituximab as second line after anti-TNF therapy
option in patients with RA with a value of E21 970 per
QALY from the societal perspective (lifetime). Applying
the same 3.5% discount rate used by Rubbert et al.
[40], we estimate a cost per QALY for ETN in patients
with severe AS in Germany of E20 626.
When calculated from the SHI perspective (direct costs
only), the ICERs for Germany are higher than in the UK
case where an identical method was used [5] and in com-
parison with published cost per QALY estimates of TNF-a
in AS patients in several other countries [5–11]. These
discrepancies can in part be explained by the difference
in the price of ETN between countries. For example, when
re-estimating our base case for the same price used in the
TABLE 3 Breakdown of costs and time horizons incurred for a cohort of 1000 patients over four time periodsa
Time horizon, years 2 5 10 15 25
Total discounted QALYs
ETN 1203 2651 4391 5567 6882
Comparator 881 1925 3272 4246 5408
Incremental QALYs 321 726 1119 1321 1475
Total discounted costs
SHI perspective, E
ETN 33 722 705 67 593 710 104 118 798 126 065 590 148 142 209
Comparator 9 076 304 21 416 471 38 065 931 50 808 175 67 314 541
Incremental costs 24 646 401 46 177 239 66 052 866 75 257 415 80 827 668
Societal perspective, E
ETN 44 642 335 98 381 356 168 052 770 220 668 395 291 300 065
Comparator 28 977 505 72 554 479 134 676 669 185 668 742 258 642 475
Incremental costs 15 664 830 25 826 877 33 376 100 34 999 652 32 657 590
Incremental cost per QALY, E
SHI perspective 76 757 63 584 59 006 56 963 54 815
Societal perspective 48 786 35 563 29 815 26 492 22 147
aFor 1000 patients in each treatment arm.
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UK study (E202 for 50 mg) this yields an ICER of E21 803
(SHI) by 25 years or equivalent to £19 284 per QALY.
Ara et al. [5] estimated an ICER of £22 704 per QALY for
the UK.
Variables in the German analysis, as with the UK eco-
nomic evaluation [5], were found to have the largest
impact on results included health utility values and
long-term withdrawal rates for ETN. Ara et al. [5] addition-
ally found that using the 95% CIs for annual AS disease
costs had a large impact on results (based on UK Stoke
data set regression, n= 147 cases) with ICERs ranging
from 9.3 to 57.2% compared with the base case. Our
results for Germany do not vary to such a degree with
ICERs ranging from 5.5 to 13.9%. Our cost regressions
are also based on a larger sample size and therefore might
be expected to be subject to less variability/uncertainty.
In terms of assessment of costs, this study has ad-
dressed direct as well as indirect, an important addition
to the current literature on the cost-effectiveness of TNF-a
treatment in patients with AS [5]. The disease costs used
in this study are representative of those accrued by pa-
tients with AS attending outpatient centres in Germany.
In the UK study using BASDAI/BASFI measurements of
20, 50 and 80, the annual diseases costs (assumed
2006 prices—without inflation) were estimated to be
E0.7K, E1.6K and E2.9K, respectively (2006 year average
of 1E= GBP 0.68434). We estimate the approximate cor-
responding average annual disease costs in Germany
(e.g. BASDAI groups) to be E3.5K, E3.8K and E4.6K, re-
spectively. Therefore, annual disease costs are in general
much higher in Germany’s AS populations compared
with those in the UK.
With regard to definition of treatment response used in
the present study, it may be argued that using the BSR
guidelines may be too restrictive for defining response
within the Germany setting and that actually trial criteria
for defining response are more appropriate. In the current
model, regression equations are used to predict treatment
response at Weeks 12 and 24 according to BSR criteria.
These regression equations might be interpreted as gen-
erating initial response rates somewhat lower than would
be the case if the criteria for treatment response used
excluded the spinal VAS. For example, in the key trials,
response rates were 66.7 vs 72.8% and 55.4 vs 69.2% at
Weeks 12 and 24 respectively, for ETN. Presumably pa-
tients’ BASDAI and BASFI measurements would also be
different due to the difference in definition of treatment
response (i.e. including or excluding the spinal VAS).
Running the model with the current set of BSR criteria as-
signed mean values to represent treatment response.
Assuming BSR criteria in this situation may be considered
an essentially conservative approach for the estimation of
costs and benefits for reflecting the German setting.
Assuming higher treatment (%) response rates, may
better reflect a situation in which less rigid criteria were
used. To explore the impact of this assumption, we per-
formed a sensitivity analysis using these upper confidence
limits for initial response estimated from individual
patient-level trial data [16]. This assumption involved as-
signing more subjects to the status treatment responder at
Weeks 12 and 24, i.e. for ETN treatment, moving from 67 to
83% and from 56 to 77%, respectively. The resulting ICER
improved (decreased) by 30.6 and 77.5% for SHI and so-
cietal perspectives, respectively [(Table 4(i)]. Alternative
assumptions on the initial response rate were not reported
in the Ara et al.’s publication [5] to enable comparisons
with our findings for Germany. The study has several limi-
tations. First, for a number of model parameters,
German-specific data were not available. For example,
clinical data on long-term disease progression either
while responding to treatment or long-term natural pro-
gression were not based on a uniquely German-treated
AS patient population. That being said, even in the UK
model, some assumptions were not derived from solely
UK-treated AS patient populations or studies, but rather
international trials and available publications [18, 22].
AS-related utilities in the UK model were based on data
collected during the European trial (AS314) and therefore
were neither strictly UK nor German specific. Some other
parameters are generally unknown for the time being in
ETN-treated AS populations such as duration of protec-
tion/response [although up to 4 years has been reported in
open label extension (OLE)]. Assumptions on treatment
effectiveness over the long term had to be made, which
were, however, varied in sensitivity analysis wherever pos-
sible. It was shown for instance that the influence of dis-
ease progression assumptions on the cost-effectiveness
results was considerably lower than the effect from varying
withdrawal rate or health utilities.
On the matter of estimating health utilities (which have a
large impact on our study results), QALY values are pro-
duced from both direct measurements using patients’
preferences and an indirect calculation method using gen-
eral population preferences, and due to differences in the
health states they describe and their different approaches
to deriving utility values they may give different costs per
QALY. Direct methods include the VAS, standard gamble
and time trade-off techniques. Indirect instruments
FIG. 2 Tornado plot of one-way sensitivity analyses for
the 25-year horizon. (a) SHI cost perspective. (b) Societal
cost perspective.
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include the Health Utilities Index, the Quality of Well-Being
scale and the EQ-5D. There is some disagreement in lit-
erature on the best approach and choice of instrument,
but the EQ-5D is the most widely evaluated and applied
[41]. The latter is part of NICE’s reference case for con-
ducting cost–effectiveness analysis and stipulates that the
measurement of changes in HRQoL should be reported
directly from patients, and the value of changes in
patients’ HRQoL (that is, utilities) should be based on
public preferences using a choice-based method, prefer-
ably using the EQ-5D [42]. However, given that there is
currently no preferred method of calculating QALY, it is
recommended that different approaches are compared
[41, 43]. When adopting a broader societal perspective,
it has been argued that economic evaluations should in-
clude all potential health benefits as well as all potential
costs [44]. Decision makers need to be able estimate the
impact of ETN in the treatment of severe AS on long-term
effectiveness, costs and cost-effectiveness in order to
decide which therapies are of greatest clinical as well
as economic value. Interpretation of the economic model-
ling results for Germany is limited as no explicit cost-
effectiveness acceptability threshold exists in Germany
to determine whether a health care intervention is
cost-effective, and good use of resources, vs one that is
regarded as representing poor value for money. There is
no definite consensus on an acceptable threshold of cost–
effectiveness ratio and how much society is willing to pay
for health improvements. However, in the USA, $50 000
per QALY is a threshold commonly used to delineate
cost-effectiveness. Cost-effectiveness thresholds for
interventions in England and Wales National Health
Service, by NICE are estimated to be £30 000 per add-
itional QALY [45] for what is acceptable to society. An
ICER <E50 000 per QALY has been cited in the recent
rheumatology literature in relation to biologic therapy for
RA [46–48], and recently a theoretical cost-effectiveness
threshold of E60 000/QALY has been suggested in the
literature for Germany to represent a cost-effective treat-
ment [49]. Taking E50 000 QALY as a hypothetical ceiling
threshold, most of our analyses (e.g. Table 4) are higher
than this value (from the SHI perspective) and well below
this value (from the societal perspective). Moreover, it is
notable that Nord et al. [50] recently raised the question
as to whether one single method of valuation (e.g. direct
or societal) is indeed sufficient to inform priority setting
in different contexts when valuing and comparing inter-
ventions and treatment programmes for people with dif-
ferent degrees of severity of illness and different potentials
for health. Nord suggests as an alternative approach
‘ . . . fair deliberative processes could be used to deter-
mine a range of cost-per-QALY thresholds according
to context (rather than modifying the QALY itself).
Such an approach could consist in establishing a set
of ‘‘priority classes’’ to which treatments are assigned
according to other criteria than cost-effectiveness
(for instance, the severity of the condition, the lack of
better treatment alternatives, or special end-of-life
considerations) . . . ’.
In the current study, estimates of treatment effective-
ness are based on patients with severe AS treated within
an RCT setting. It is therefore important that studies also
examine the cost-effectiveness within a real world setting.
The use of observational data (e.g. on response and dis-
continuation rates) would enable an assessment of the
current study’s external validity to be more precisely
determined. In addition, the place of ETN in the treatment
of patients with severe AS against the broader spectrum
of treatment of patients is mentioned in the revised ver-
sions of our manuscript. For example, examination of the
entire NCCRD cohort (real practice data for German AS
patients for 2007) according to International Statistical
Classification of Diseases and Related Health Problems
10th Revision codes with valid data for BASDAI and
BASFI revealed that almost half of these patients received
biologics (587/1035). The other patients received other
drugs such as NSAIDs.
For AS patients not receiving biologics, 193/433 had
BASDAI scores of >4.0 and 83/220 had BASFI scores of
>4.0. The mean BASDAI score for AS NCCRD cohort pa-
tients receiving biologic therapy is 3.6 (S.D. 2.2). Thus,
NCCRD data suggest that the use of biologic therapies
in AS patients only with e.g. BASDAI scores of 54 is not
necessarily the situation with regard to treating the
broader spectrum of AS patients in real life, i.e. the prac-
tice of using biologics appears to be somewhat less re-
strictive/stringent in real clinical German practice. In
contrast, a Spanish study of AS patients commencing bio-
logic therapy had a reported mean BASDAI score of 4.5
[51]. On the other hand, a population-based cohort of pa-
tients with AS commencing biologic therapy extracted
from a national biologic registry in Australia, found that
in comparison with participants in RCTs of biologic ther-
apy [16, 17], Australian Rheumatology Association
Database AS participants were older (mean age 45.1 vs
41.9 years), had a longer disease duration (mean 18.5 vs
12.6 years) and had higher baseline BASDAI scores (mean
7.6) already having significant comorbidities.
Oldroyd et al. [52] also make the point that ‘comparable
efficacy between RCTs and clinical practice is hardly ever
achieved due in part to patient selection, differences in
co-medications and co-morbidites and treatment adher-
ence’. Therefore, the participants in RCTs of biologic
therapies for AS may not be entirely representative of
German patients with AS commencing biologic therapies
in routine care. For example, being older, having longer
disease duration and more active disease, a history of
verified malignancy, all these points highlight the import-
ance of systematically collecting post-marketing longitu-
dinal outcome data for biologic therapy in routine care.
For example, it has been emphasized that registries and
observational data sets should examine reasons and rates
of withdrawal and mortality and follow the sequence of
treatments given to patients, as well as incorporating eco-
nomic end points (HRQoL and costs) [53, 54].
Apart from cost-effectiveness, it is of equal relevance
how much resources will be required to finance a biologic
therapy programme including ETN for several decades,
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thus addressing the question of whether long-term ETN
treatment is affordable (i.e. the net budget impact). This
objective was beyond the scope of the current study.
A broad societal perspective on value, i.e. costs and
benefits, facilitates informed discussion and decisions
about access and use of new medical technologies.
Non-medical costs and production losses dominate
costs in AS (further demonstrated in this study) and it
has been argued that economic evaluation should there-
fore adopt a societal perspective [9]. The purpose of eco-
nomic evaluations conducted on behalf of many national
Health Technology Assessment agencies, including NICE
(UK), Canadian Agency for Drugs and Technologies in
Health (Canada) and Institute for Quality and Efficiency
in Health Care in the German context, do not currently
recommend a broad societal (cost) perspective on value
in HTA studies aimed at informing decisions (advising
payers) about allocation of resources. If productivity
losses are substantially affected by a new health technol-
ogy, consideration could be given to including them as a
health benefit side, although this is controversial.
Whatever estimation method is used to calculate indirect
costs, these costs should be reported separately with full
accounting of the cost content and method employed.
The current study followed this overall approach.
Conclusion
Cost-effectiveness results for ETN in patients with severe
AS in Germany are considerably different depending on
whether a SHI (direct costs only) or a societal (direct plus
indirect costs) viewpoint is considered. In Germany as
well as in other European countries, AS patients are
often affected at a relatively young age which makes the
disease’s impact on work productivity (and hence indirect
costs) a substantial burden on German society. The treat-
ment of severe AS with ETN compares favourably with
anti-TNF treatments in other rheumatic diseases in
Germany.
Rheumatology key messages
. Treatment of severe AS with ETN has comparable
cost-effectiveness to anti-TNF treatment of other
rheumatic diseases in Germany.
. Results demonstrate substantial economic benefits
when taking a societal cost perspective.
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